Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting
Clinical Lung Cancer · 2023
DOI: 10.1016/j.cllc.2023.03.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2023. Verfasst von Anthony N Sireci und 9 weiteren Autor:innen. Beteiligte Einrichtung: Loxo@Lilly, Indianapolis, IN. Electronic address: asireci@loxooncology.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION/BACKGROUND: This study was designed to describe real-world changes in biomarker testing among patients with non-squamous, metastatic non-small cell lung cancer (mNSCLC) in a community oncology setting from 2015 to 2020. PATIENTS AND METHODS: This retrospective study randomly selected 500 adult patients diagnosed with nonsquamous mNSCLC to undergo chart review and data extraction. Data were extracted and validated by 2 independent abstractors. Biomarker testing rates were described before and after national guideline updates and FDA approval of targeted agents. RESULTS: At least 1 biomarker test was received by 89.4% of patients with mNSCLC. Of all patients, 46.6%, 34.6%, and 8.2% received both single-gene and next generation sequencing (NGS)-based testing, single-gene testing only, and NGS-based testing only, respectively. However, there were changes in testing rates at the time of drug approvals for targeted agents. Biomarker testing increased for ALK (45.0% before to 78.3% after ALK-targeted drug approval), BRAF (from 20.0% to 67.8%), EGFR (from 20.0% to 78.2%), NTRK (from 34.6% to 55.7%), and ROS1 (increased from 29.6% before approval to 74.2% after). Biomarker testing increased after changes were made to national guidelines for BRAF (from 18.8% before to 68.1% after inclusion in guidelines), NTRK (from 37.2% to 56.5%), and ROS1 (increased from 40.8% to 74.5% after guideline updates). Targeted therapy was received by 62.4% of patients with a positive biomarker. CONCLUSION: Increases in biomarker testing rates were observed relative to targeted agent approvals and national guideline updates. However, many patients with non-squamous mNSCLC did not receive full genotyping in accordance with national guidelines and represent an opportunity to identify reasons and solutions for barriers to care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Loxo@Lilly, Indianapolis, IN. Electronic address: asireci@loxooncology.com.
- Loxo@Lilly, Indianapolis, IN.
- Eli Lilly and Company, Indianapolis, IN.
- Xcenda, Carrollton, TX.
- IntrinsiQ, Carrollton, TX.
Zitieren
APA
Sireci, A. N., Krein, P. M., Hess, L. M., Khan, T., Willey, J., Ayars, M., Deyoung, K., Bhaskar, S., Mumuney, G., & Coutinho, A. (2023). Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.03.002
Vancouver
Sireci AN, Krein PM, Hess LM, Khan T, Willey J, Ayars M, et al. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting. Clinical Lung Cancer. 2023. doi:10.1016/j.cllc.2023.03.002
BibTeX
@article{Sireci2023,
author = {Sireci, Anthony N and Krein, Peter M and Hess, Lisa M and Khan, Taha and Willey, Joanne and Ayars, Michael and Deyoung, Kathryn and Bhaskar, Sandhya and Mumuney, Ganiat and Coutinho, Anna},
title = {Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting},
journal = {Clinical Lung Cancer},
year = {2023},
doi = {10.1016/j.cllc.2023.03.002}
}
EUVIMED